Skip to content

Linked Color Imaging Based CMV Diagnosis for Gastric Mucosal Lesions

CMV Criteria in the Detection of Gastric Diseases Using Linked Color Imaging

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03092414
Enrollment
2000
Registered
2017-03-27
Start date
2017-05-31
Completion date
2017-08-31
Last updated
2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Disease

Brief summary

The newly developed linked color imaging (LCI) system (FUJIFILM Co.) creates clear and bright endoscopic images by using short-wavelength narrow-band laser light combined with white laser light on the basis of BLI technology. This system can obtain bright endoscopic images even at a distant view because LCI has more intense white light than the short-wavelength narrow-band laser light. Short-wavelength narrow-band laser light enhances the vessels on the mucosal surface and the patterns of the mucosa. Therefore, LCI may facilitate the detection of gastric mucosal lesions. Further studies are needed to confirm the clinical utility of LCI.

Detailed description

LCI enhances differences in hue, in the red region of the spectrum, through digital processing. This makes red areas appear redder and white areas appear whiter. Thus, it is easier to recognize a slight difference in color of the mucosa. Based on previous experience, a new LCI based endoscopic diagnosis criteria called CMV (color- microstructure-vessel) criteria has been proposed, which could be used for judging the gastric mucosal lesions. LCI has the advantage of detecting color changes of the mucosa, and this could provide very valuable and useful evidence for making endoscopic diagnosis. In this study, a blinded random controlled clinical trial is designed to further validate the diagnostic value of LCI based CMV criteria for gastric diseases.

Interventions

The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.

The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.

Sponsors

Affiliated Hospital to Academy of Military Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Above 18 years old patients * Who agree to participate in the study * Patients with the indications for gastroduodenoscopy

Exclusion criteria

* Patients, who were receiving nonsteroidal anti-inflammatory drugs, pump inhibitors (PPI) or antibiotics in the last 3 weeks. * Severe uncontrolled coagulopathy * Prior history of gastric surgery. * Pregnancy and lactation

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy4 monthsDiagnostic accuracy of LCI for gastric diseases was calculated by comparing the LCI endoscopic diagnosis with pathological diagnosis.

Secondary

MeasureTime frameDescription
Numbers of lesions in the stomach4 monthsThe numbers of lesion detected under WLE and LCI will be recorded and compared.
Endoscopic examination duration4 monthsThe time spent on the endoscopic examination using WLE and LCI will be compared.

Countries

China

Contacts

Primary ContactXiaotian Sun, M.D., Ph.D.
xiaotian-sun@hotmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026